Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Phase 1a/?1b Study of IGM-8444 Alone and in Combination in Subjects With Relapsed, Refractory, or Newly Diagnosed Cancers
Complete Title: An Open-Label, Multicenter, Phase 1a/1b Study of Igm-8444 as a Single Agent And In Combination in Subjects with Relapsed, Refractory, or Newly Diagnosed Cancers
Trial Phase: I
Investigator: Vivian Oehler
This study is a first-in-human, Phase 1a/1b, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of IGM-8444 as a single agent and in combination in subjects with relapsed and/or refractory solid or hematologic cancers, as well as newly diagnosed cancers, and an open-label, randomized study of IGM-8444+FOLFIRI (± bevacizumab).
Keywords:
- Leukemia, Acute Myeloid (AML)
- Leukemia, Chronic Lymphocytic (CLL)
- Lymphoma, Non-Hodgkin (NHL)
- Sarcoma
- Solid Tumors
- Colorectal Neoplasms
- Lymphoma, Small Lymphocytic (SLL)
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
I
Vivian Oehler
RG1123124
NCT04553692
An Open-Label, Multicenter, Phase 1a/1b Study of Igm-8444 as a Single Agent And In Combination in Subjects with Relapsed, Refractory, or Newly Diagnosed Cancers
Leukemia, Acute Myeloid (AML)
Leukemia, Chronic Lymphocytic (CLL)
Lymphoma, Non-Hodgkin (NHL)
Sarcoma
Solid Tumors
Colorectal Neoplasms
Lymphoma, Small Lymphocytic (SLL)